



S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market

S2Medical AB (publ) ("S2Medical"), a leading developer of medical devices, is proud to announce that we have entered into an exclusive distribution agreement with Provas Medical Ltd ("Provas Medical") for the sale of products in the Epiprotect series on the Turkish market.

This three-year agreement marks a significant milestone for S2Medical's expansion and presence in the Middle East and will strengthen the company's position as a pioneer in wound healing. The agreement entails commitments from Provas Medical to place orders worth approximately 4.7 million Swedish kronor, provided that S2Medical's products are successfully registered in Turkey.

Provas Medical has a strong presence in Turkey and will play a key role in introducing the Epiprotect series to the Turkish market. S2Medical looks forward to a successful collaboration with Provas Medical and to improving the quality of life for patients through access to top-tier wound healing.

"We are excited about the partnership with Provas Medical and the opportunities it opens up for S2Medical. This agreement is a testament to the global demand for our Epiprotect products and our ability to expand our reach to new and promising markets," says Mårten Skog, COO of S2Medical AB (publ).

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-11-2023 16:09 CET.

Contact Details

Petter Sivlér – CEO, S2Medical AB (publ)

Telephone: +46 (0)8-70 000 50

E-mail: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB

Telephone +46 (0)8-580 065 99

Website: www.vatorsec.se

E-mail: ca@vatorsec.se

About S2Medical

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084